Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 275Carcinoma, Intraductal, Noninfiltrating 25Breast Carcinoma In Situ 21Breast Neoplasms, Male 12Neoplasm Metastasis 10Neoplasms 7Inflammatory Breast Neoplasms 7Breast Cancer Female 4Obesity 3Endometrial Neoplasms 3Carcinoma, Ductal, Breast 3Breast Diseases 3Sleep Wake Disorders 2Hot Flashes 2ER+ Breast Cancer 2Carcinoma, Lobular 2Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Risk Reduction Behavior 1Recurrence 1Pulmonary Fibrosis 1Primary Breast Cancer 1Premenopausal Breast Cancer 1Precancerous Conditions 1Patient Acceptance of Health Care 1Paget's Disease, Mammary 1Ovarian Neoplasms 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Tamoxifen × Breast × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡